Advances and challenges in the treatment of myasthenia gravis
The article discusses advances and challenges in the treatment of MG. Standard treatments may not be effective for all patients, leading to the need for new therapeutic approaches. The article highlights emerging immunotherapies that target specific components of the immune system involved in MG pathogenesis (the underlying cause of the disease). These therapies include T-cell directed monoclonal antibodies, B-cell directed therapies, complement inhibitors, and drugs that inhibit the FcRn receptor. These therapies aim to stop some of the mechanisms that cause MG through various methods such as: reduce T- and B-cell activity, deplete plasma cells, inhibit complement activation, and inhibit the recycling of pathogenic autoantibodies. The article also mentions ongoing clinical trials evaluating the safety and efficacy of these new treatments. Overall, these new therapeutic options show promise but also present challenges in terms of optimizing treatment strategies and understanding their mechanisms of action.